NasdaqGM:IMRXBiotechs
Why Immuneering (IMRX) Is Down 29.7% After Phase 2a Pancreatic Data Versus Historical Benchmarks And Phase 3 Plan
Immuneering Corporation recently reported updated Phase 2a data showing encouraging overall survival, response, and safety outcomes for its atebimetinib plus modified gemcitabine/nab-paclitaxel regimen in previously untreated pancreatic cancer patients, and confirmed plans to begin a pivotal Phase 3 trial in mid-2026.
A key nuance is that the reported survival benefit is based on comparisons to historical MPACT trial benchmarks rather than a head-to-head control arm, which may influence how...